RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.
Kaisrlikova M, Vesela J, Kundrat D, Votavova H, Dostalova Merkerova M, Krejcik Z, Divoky V, Jedlicka M, Fric J, Klema J, Mikulenkova D, Stastna Markova M, Lauermannova M, Mertova J, Soukupova Maaloufova J, Jonasova A, Cermak J, Belickova M.
Kaisrlikova M, et al. Among authors: belickova m.
Leukemia. 2022 Jul;36(7):1898-1906. doi: 10.1038/s41375-022-01584-3. Epub 2022 May 3.
Leukemia. 2022.
PMID: 35505182
Free PMC article.